This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
November 30, 2020
Nordic Nanovector announces change of its Oslo Børs ticker symbol to “NANOV”
November 24, 2020
Strongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in the Journal, Pituitary
November 24, 2020
Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma
November 19, 2020
SynOx Therapeutics raises €37M in Series A Financing
November 19, 2020
INTERIM REPORT Q3 2020
November 19, 2020
Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial
November 19, 2020
Nordic Nanovector ASA: Results for the Third Quarter 2020
November 18, 2020
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
November 18, 2020
SPRUCE BIOSCIENCES REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
November 16, 2020
Vicore Pharma recruits the first patient in the phase II Proof-of-Concept study in idiopathic pulmonary fibrosis